PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Mereo BioPharma Grp (MPH)

Mereo BioPharma Grp

Block Listing Application
RNS Number : 1223S
Mereo BioPharma Group plc
06 July 2020
 

Mereo BioPharma Group plc

 

 (" Mereo " or the "Company")

 

Block Listing Application

 

London and Redwood City, Calif., July 6, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, announces that an application has been made to the London Stock Exchange for a block listing of 60,000,000 ordinary shares of £0.003 each in the Company ("Ordinary Shares").

 

These Ordinary Shares will be issued from time to time in order to satisfy the requirement to allot shares pursuant to the exercise of warrants to subscribe for new Ordinary Shares ("Warrants") and the conversion of unsecured convertible loan notes due 2023 into new Ordinary Shares ("Notes").  The Warrants and Notes were issued as part of the recently completed fundraising announced on 4 June 2020.

 

It is expected that admission will become effective on 9 July 2020. The Ordinary Shares under the block listing will rank pari passu with the Company's existing Ordinary Shares.

 

About Mereo BioPharma

Mereo BioPharma is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for patients with oncology and rare diseases. Mereo's strategy is to selectively acquire product candidates for oncology and rare diseases that have already received significant investment from pharmaceutical and large biotechnology companies and that have substantial preclinical, clinical and manufacturing data packages. Mereo's lead oncology product candidate, etigilimab, an anti-TIGIT, has completed a Phase 1a and Phase 1b for a range of solid tumor types and the second product candidate, navicixizumab, for ovarian cancer has been licensed to Oncologie Inc. for up to $300M in milestone payments. Mereo's lead rare disease product candidate, setrusumab, has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta ("OI") and a pivotal Phase 3 study design in paediatrics has been agreed with the FDA and EMA. Mereo's second lead product candidate, alvelestat, is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency ("AATD"). Mereo plans to form a strategic partnership for setrusumab prior to initiation of the paediatric pivotal study.

 

Mereo BioPharma Contacts:

 

Mereo

+44 (0)333 023 7300

Denise Scots-Knight, Chief Executive Officer




Cantor Fitzgerald Europe (Nominated Adviser and Broker to Mereo )

+44 (0)20 7894 7000

Phil Davies


Will Goode




Burns McClellan (US Public Relations Adviser to Mereo)

+01 (0) 212 213 0006

Lisa Burns


Steve Klass




FTI Consulting (UK Public Relations Adviser to Mereo )

 +44 (0)20 3727 1000

Simon Conway


Ciara Martin




Investors

investors@mereobiopharma.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
ALSFIFVTDLIRIII
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close